Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Penumbra (PEN)
NYSE:PEN
Penumbra (PEN) Stock Price & Analysis
372 Followers
PEN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$180.93 - $348.67
Previous Close$191.34
Volume361.04K
Average Volume (3M)332.99K
Market Cap
$7.42B
Enterprise Value$7.40B
Total Cash (Recent Filing)$248.85M
Total Debt (Recent Filing)$228.79M
Price to Earnings (P/E)80.5
Beta1.23
Next Earnings
Aug 05, 2024EPS Estimate
$0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.38
Shares Outstanding38,764,917
10 Day Avg. Volume217,597
30 Day Avg. Volume332,985
Standard Deviation0.14
R-Squared0.05
Alpha0.00978
Financial Highlights & Ratios
Price to Book (P/B)7.94
Price to Sales (P/S)8.76
Price to Cash Flow (P/CF)51.50
P/FCF Ratio49.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.43
Enterprise Value/Gross Profit13.82
Enterprise Value/Ebitda140.24
Forecast
1Y Price Target
$265.89Price Target Upside41.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
Penumbra News
Bulls Say, Bears Say
Bulls Say
EarningsPEN's Q1 result came in ahead of expectations with a top-line beat and EPS beat.
Market Share+35% US thrombectomy growth and market share gains in US neuro thrombectomy indicate strong performance and competitive positioning.
Product DevelopmentThe company's ongoing and upcoming new product cycle provides line-of-sight to sustainable mid-to-high-teens growth into the future.
Bears Say
Clinical TrialsEnrollment for clinical trials lagged due to restrictive inclusion criteria and competition from other trials, potentially delaying product development and future revenue streams.
Financial PerformanceEmbolization and Access segment experienced a decline, reflecting weaker performance in a key product line.
Product Sales GrowthThrombectomy growth slowed significantly, indicating a loss of momentum in a previously high-growth area.
---
Ownership Overview
6.14% Insiders
46.55% Mutual Funds
44.52% Other Institutional Investors
2.78% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PEN FAQ
What was Penumbra’s price range in the past 12 months?
Penumbra lowest stock price was $180.93 and its highest was $348.67 in the past 12 months.
What is Penumbra’s market cap?
Currently, no data Available
When is Penumbra’s upcoming earnings report date?
Penumbra’s upcoming earnings report date is Aug 05, 2024 which is in 66 days.
How were Penumbra’s earnings last quarter?
Penumbra released its earnings results on May 07, 2024. The company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.386 by $0.024.
Is Penumbra overvalued?
According to Wall Street analysts Penumbra’s price is currently Undervalued.
Does Penumbra pay dividends?
Penumbra does not currently pay dividends.
What is Penumbra’s EPS estimate?
Penumbra’s EPS estimate is $0.57.
How many shares outstanding does Penumbra have?
Penumbra has 38,764,915 shares outstanding.
What happened to Penumbra’s price movement after its last earnings report?
Penumbra reported an EPS of $0.41 in its last earnings report, beating expectations of $0.386. Following the earnings report the stock price went down -3.29%.
Which hedge fund is a major shareholder of Penumbra?
Among the largest hedge funds holding Penumbra’s share is PRIMECAP Management Co. It holds Penumbra’s shares valued at 10M.
---
Penumbra Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$265.89 (41.40% Upside)
$265.89 (41.40% Upside)
Blogger Sentiment
Bullish
PEN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 68.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $38.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 3.5%
Last 30 Days ▼ 3.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.57%
12-Months-Change
Fundamentals
Return on Equity
8.38%
Trailing 12-Months
Asset Growth
13.23%
Trailing 12-Months
Company Description
Penumbra
Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers thrombectomy, embolization, access, neurosurgical tools, ruby coil system, lantern, penumbra occlusion device (POD) system, packing coil, and indigo systems products. Its target markets include interventional neuroradiologists, neurosurgeons, and interventional neurologists; and interventional radiologists, vascular surgeons, and interventional cardiologists. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004 and is headquartered in Alameda, CA.
---
PEN Earnings Call
Q1 2024
0:00 / 0:00
---
PEN Stock 12 Month Forecast
Average Price Target
$265.89
▲(41.40% Upside)
Technical Analysis
Best Analysts Covering PEN
1 Year
1 Year Success Rate
11/21 ratings generated profit
1 Year Average Return
+3.69%
reiterated a buy rating 8 months ago
Copying Joanne Wuensch's trades and holding each position for 1 Year would result in 52.38% of your transactions generating a profit, with an average return of +3.69% per trade.
---